Further studies on long-term Triac treatment in real-life settings confirmed the beneficial effects of Triac on the peripheral phenotype of MCT8-deficient patients and its clinical potential in AHDS [52]. The gene discussed is SLC16A2; the disease is Allan-Herndon-Dudley syndrome.